Abstract
Microbia Inc is developing the oral guanylate cyclase C agonist linaclotide, a 14mer peptide for the potential treatment of constipation- predominant irritable bowel syndrome and chronic idiopathic constipation. Phase II clinical trials are underway for both indications.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 403-410 |
| Number of pages | 8 |
| Journal | Current Opinion in Molecular Therapeutics |
| Volume | 9 |
| Issue number | 4 |
| State | Published - Aug 2007 |
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
- Pharmacology
- Drug Discovery
- Genetics(clinical)